# Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

> **NCT03521245** · — · UNKNOWN · sponsor: **OmicsWay Corp.** · enrollment: 40 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **OTHER:** RNA sequencing
- **OTHER:** Transcriptome analysis
- **DRUG:** Trastuzumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03521245
- **Lead sponsor:** OmicsWay Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-09-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03521245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03521245, "Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03521245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*